Two Sigma Investments
KNSA icon

Two Sigma Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Two Sigma Investments’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3M Sell
420,914
-109,582
-21% -$4.85M 0.02% 938
2025
Q4 		$21.9M Buy
530,496
+68,726
+15% +$2.76M 0.03% 692
2025
Q3 		$17.9M Buy
461,770
+298,030
+182% +$9.68M 0.03% 673
2025
Q2 		$4.53M Buy
+163,740
New +$4.17M 0.01% 1278
2021
Q3 		– Sell
-49,232
Closed -$686K – 4485
2021
Q2 		$686K Buy
+49,232
New +$748K ﹤0.01% 2823
2021
Q1 		– Sell
-55,826
Closed -$986K – 4045
2020
Q4 		$986K Sell
55,826
-219,618
-80% -$3.86M ﹤0.01% 2023
2020
Q3 		$4.22M Buy
275,444
+204,219
+287% +$3.83M 0.02% 881
2020
Q2 		$1.81M Buy
71,225
+52,436
+279% +$1.1M 0.01% 1150
2020
Q1 		$291K Buy
18,789
+578
+3% +$9.04K ﹤0.01% 2327
2019
Q4 		$201K Buy
+18,211
New +$158K ﹤0.01% 3420
2018
Q4 		– Sell
-13,442
Closed -$343K – 3275
2018
Q3 		$343K Buy
+13,442
New +$261K ﹤0.01% 2687

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Two Sigma Investments's KNSA Position: Q1 2026 in Review

Two Sigma Investments reduced its Kiniksa Pharmaceuticals (KNSA) stake by 21% in Q1 2026, selling an estimated $4.85M and leaving 420,914 shares worth $20.3M. The position accounts for 0.02% of the portfolio, ranked #938.

Two Sigma Investments first reported a position in KNSA in Q3 2018 and has held it in 11 quarters since. The position peaked at $21.9M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Two Sigma Investments held 420,914 shares of Kiniksa Pharmaceuticals worth $20.3M as of Q1 2026.
  • Two Sigma Investments sold 109,582 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $4.85M.
  • Kiniksa Pharmaceuticals made up 0.02% of Two Sigma Investments's portfolio in Q1 2026, its #938 holding.
  • Two Sigma Investments first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 11 quarters since.
  • Two Sigma Investments's Kiniksa Pharmaceuticals position peaked at $21.9M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.